Sleuthinsights

Sleuth (Sleuth Insights) — Proprietary therapeutic-class pipeline and commercial-performance database, refreshed to a stated as-of date (August 2026): every active program in a class is catalogued and classified by development stage (343 preclinical / 14 IND / 95 Phase 1-1/2 / 51 Phase 2-2/3 / 51 Phase 3 / 24 filed / 50 approved), by developer headquarters country, by mechanism with a target-pairing taxonomy (124 unique combination pairings), by route of administration (injectable vs oral), and by indication expansion (181 cardio-renal-metabolic incretin programs), then joined to disclosed br…

Sleuthinsights offers (Alternative, Fundamental) — 628 active GLP-1 and metabolic programs at the August 2026 cut with full stage, geography, mechanism-pairing and route classification; 124 distinct mechanism pairings; 181 cardio-renal-metabolic incretin programs; brand-level sales series across at least six named products with prior-year comparatives; plus parallel class-level datasets in the publisher's other franchises (biopharma duopolies, obesity access), implying a multi-thousand-program cross-therapeutic universe and multiple quarterly editions per year.

Thematic and event-driven biotech equity research on the metabolic/obesity complex (pipeline saturation, catalyst dating, share-of-class); pharma strategy and business-development screens for in-licensing China-origin assets and for combination/muscle-sparing white space; competitive positioning and product-profile gap analysis (oral convenience, tolerability, lean-mass preservation); payer and market-access modelling using persistence and discontinuation series; class-level market sizing and forecast inputs; corporate-development monitoring of duopoly BD coverage; and ML training targets for programme-success and me-too-risk models where the analyst stage/innovation/pairing labels are the supervision signal

The data is with 3 years of history.